Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

out any unexpected side effects," stated Jean-Pierre Delord, M.D., principal investigator from the anti-cancer center Claudius Regaud Institute in Toulouse, France. "In particular, no severe toxicity has been observed even after the administration of six cycles of the agent in this Phase I trial. Furthermore, we have observed some encouraging activity in normally chemo-resistant cancers."

DTS-201 was initially discovered by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium, and exclusive European rights were in-licensed from Medarex Inc. in April 2003 as a preclinical compound.

President and CEO of Diatos John Tchelingerian, Ph.D, added: "I am satisfied that Diatos continues to make substantial progress in its clinical development programs based on novel, targeted anti-cancer chemotherapies. The positive results from our Phase I study with DTS-201, particularly the encouraging signs of improved efficacy versus standard doxorubicin treatment, represent a significant milestone in the development of our product. Diatos is poised to initiate a Phase II study for DTS-201 in Europe soon, advancing what we believe is a next generation anthracycline for the benefit of cancer patients."

Notes to Editors:

About DTS-201

DTS-201 consists of doxorubicin, a marketed cytotoxic agent effective against a wide variety of solid tumors, conjugated to a proprietary peptide. The product was discovered in 1996 by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium and in-licensed from Medarex Inc in April 2003. DTS-201 is also known as Super-Leu-Dox or CPI-0004Na in the USA.

DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. It consists of the tetrapeptide N-succinyl-(beta)-alanyl-L-leucyl-L-alanyl-L-leucine covalently linked to the aminoglycoside portion of doxorubicin.

Peptide-based targeting of tumors is an attractive approach f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
(Date:9/2/2014)... , Sept. 2, 2014  Cyberonics, Inc. ... from the ANTHEM-HF clinical study.  Results of the ... during a major European cardiology congress and concurrently ... show Autonomic Regulation Therapy (ART) in patients ... impaired heart function is safe, improves the heart,s ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on ... treatment device market, Frost & Sullivan recognizes Novian ... & Sullivan Award for Technology Innovation Leadership. Novian ... fibroadenoma and malignant tumors with its proprietary technology, ... is a reliable, accurate, and easy-to-control ultrasound-guided thermo ...
Breaking Medicine Technology:Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... , CINCINNATI , June 21 ... to its HARMONIC® line of surgical devices, the HARMONIC ... designed to extend the reach of surgeons for minimally ... (or 9cm) than the standard length HARMONIC ACE® device. ...
... today announced that six-month clinical follow-up data show the safety and ... (Sequent Please®, B.Braun) followed by implantation of the company,s Genous Bio-engineered ... , , ... single center, all-comers POTENT ( P aclitaxel-eluting ball O on and ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3
(Date:9/2/2014)... The use of Xarelto (known generically ... at a rapid pace, even as Xarelto lawsuits ... the U.S., Bernstein Liebhard LLP reports. According to a ... a year of its 2011 launch, patients were just ... blood thinner that has been in use for several ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... -- Melatonin supplements did not reduce delirium in seniors ... found. Many older hospital patients experience the sudden, ... their normal sleep-wake cycle. A lack of the hormone ... but there has been little research into whether melatonin ... 378 patients, average age 84, who had hip fracture ...
(Date:9/2/2014)... LOS ANGELES (Sept. 2, 2014) Measuring the levels of ... suffer a sudden cardiac arrest, a heart rhythm disorder that ... new study, published online by the peer-reviewed journal Heart ... male sex hormone, were found in men who had a ... sex hormone, were strongly associated with greater chances of having ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2
... will develop one or more chronic health problems later in ... a study released Tuesday suggested. ,Dutch researchers ... cancer survivors found that 75 percent went on to develop ... reached their mid 20s, or early 30s at the latest. ...
... increased risk of jaw or facial bone deterioration or ... lesions, elevated levels of calcium in the blood, or ... found an association between the use of intravenous bisphosphonates ... condition in which poor blood supply to the area ...
... set to turn into a "no-smoking zone" by mid-July this year. ... be fully enforced from July 15 and will cover markets, restaurants ... users annually in the country. , ,The establishment says ... utilities will be allowed to set up a separate area for ...
... (IANS) Nearly 100 people have been bitten and injured by ... anti-rabies vaccines in the government hospitals to treat the patients. ... has attacked and injured villagers - including women and children ... of the district, about 200 km from here. ...
... program cuts diabetes risk and is more effective at ... overweight children. ,A family-based weight management ... was more successful at plummeting weight, body fat, BMI ... ,Mary Savoye-Desanti, research associate in Yale's Department of ...
... substantial progress in curbing the spread of polio with just 82 ... to 676 last year, says WHO. ,Of the ... Uttar Pradesh and 17 from Bihar, it says. ... with 585 for the same period in 2006,' said a WHO ...
Cached Medicine News:Health News:Childhood Cancer can Lead to Chronic Health Problems Later in Life: Study 2Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:Chandigarh Set to Be No-smoking Zone from July 15 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:India Records Substantial Decline in Polio Cases 2
Female Compression VEST w/sleeves...
Male Support Brief...
Ideal for lower abdominal procedures. Comes with a left side separating zipper....
Arm Compression Garment...
Medicine Products: